Our HIV vaccine approach is based on initial immunization with a replicating adenovirus (Ad) vector carrying an HIV gene(s) followed by a booster immunization with an HIV envelope protein. The Ad-HIV vaccine replicates in epithelial cells that line mucosal inductive sites, thus eliciting strong, persistent cellular immunity at mucosal effector sites as well as in the blood. We have shown that initial immunizations with an Ad-HIV vaccine also stimulates production of anti-HIV antibodies. Together, the regimen induces strong and durable protective responses. We have demonstrated that administration of Ad-HIV vaccine to the upper respiratory tract as well as to the gut (by oral immunization) elicits memory T cells that possess """"""""homing receptors"""""""" leading them to traffic to the intestine, a prime site of HIV infection. Thus the vaccine approach elicits cellular immunity at a location critical for preventing or controlling HIV infection. Recently we have explored several routes of Ad-recombinant immunization in rhesus macaques including intrarectal, intravaginal, and sublingual as well as the standard administration to the upper respiratory tract intranasally or intratracheally. Interestingly, cellular immune responses as maeasured by interferon-gamma ELISPOT and T cell proliferation assays revealed similar levels of imnmune responses were achieved in peripheral blood by all immunization routes. Administration of an Ad-GFP marker recombinant by the various routes also showed the presence of replicating Ad was similar in rectal tissue and the lung without regard to immunization route. The data suggest use of replicating Ad vectors may facilite vaccine delivery by the easiest, least invasive route. The study of NK cells, key effector cells of innate immunity, is also continuing in order to elucidate their response to Ad-HIV vaccine immunization and their cooperation with vaccine-elicited antibodies in mediating cell killing functions such as antibody-dependent cellular cytotoxicity and antibody-dependent cell mediated viral inhibition. Macaque NK cells have been characterized phenotypically by flow cytometry as a prelude to expanded functional studies. New studies have also shown the importance of CD4 T cell responses in assisting NK cell recall responses. Studies have shown that antibody activities mediated by NK effector cells that span innate and adaptive immunity are correlated with reduced viremia following viral challenge of immunized rhesus macaques. Further, new studies on NKT cells and gamma/delta T cells have recently been initiated to investigate a potential role in vaccine-mediated viremia control. We have also examined Th17 cells in vaccinated versus control macaques to determine if a vaccine which is partially protective could preserve this cell population which is important for control of microbial pathogens. We found that unfortunately, strong viremia control elicited by vaccination does not prevent gradual Th17 cell loss. The implication of this finding is that a vaccine which fully confers sterilizing protection will be necessary to prevent disease sequelae. Finally, we have been exploring use of an immune modulator to facilitate induction of cellular immunity following treatment of macaques with anti-retroviral therapy. A comprehensive picture of responses of various cell types is being compiled and will facilitate further design of both prophylactic and therapeutic vaccine regimens. Overall we have developed expanded capabilities to investigate vaccine-elicited cellular immunity by flow cytometry, as well as by expression of various cytokines and chemokines. Our studies continue to show induction of potent cellular immune responses systemically and mucosally following the replicating Ad-recombinant prime/protein boost regimen.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011062-04
Application #
8349307
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2011
Total Cost
$1,696,890
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Rahman, Mohammad Arif; McKinnon, Katherine M; Karpova, Tatiana S et al. (2018) Associations of Simian Immunodeficiency Virus (SIV)-Specific Follicular CD8+ T Cells with Other Follicular T Cells Suggest Complex Contributions to SIV Viremia Control. J Immunol 200:2714-2726
Vargas-Inchaustegui, Diego A; Helmold Hait, Sabrina; Chung, Hye Kyung et al. (2017) Phenotypic and Functional Characterization of Circulatory, Splenic, and Hepatic NK Cells in Simian Immunodeficiency Virus-Controlling Macaques. J Immunol 199:3202-3211
Morales-Kastresana, Aizea; Telford, Bill; Musich, Thomas A et al. (2017) Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Sci Rep 7:1878
Musich, Thomas; Robert-Guroff, Marjorie (2016) New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. Expert Rev Vaccines 15:1015-27
Vargas-Inchaustegui, Diego A; Demers, Andrew; Shaw, Julia M et al. (2016) Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques. J Immunol 196:1700-10
Vargas-Inchaustegui, Diego A; Xiao, Peng; Demberg, Thorsten et al. (2015) Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4? T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques. Immunology 145:288-99
Valentin, Antonio; McKinnon, Katherine; Li, Jinyao et al. (2014) Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol 155:91-107
Qureshi, Huma; GenescĂ , Meritxell; Fritts, Linda et al. (2014) Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques. PLoS One 9:e106004
Thomas, Michael A; Tuero, Iskra; Demberg, Thorsten et al. (2014) HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology 471-473:81-92
Gordon, Shari N; Doster, Melvin N; Kines, Rhonda C et al. (2014) Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol 193:6172-83

Showing the most recent 10 out of 27 publications